Sanofi India · NSE: SANOFI · BSE: 500674
Q4 FY22 results · Jan–Mar 2022
Sanofi India reported revenue from operations of ₹707.00 crore (down 2.5% from Q4 FY21) and net profit of ₹238.40 crore (up 63.4% from Q4 FY21) for Q4 FY22 (Jan–Mar 2022), on a standalone basis.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 707.00 | 725.10 | −2.5% | 687.90 | +2.8% |
| Other income | 24.40 | 26.30 | −7.2% | 16.30 | +49.7% |
| Total income | 731.40 | 751.40 | −2.7% | 704.20 | +3.9% |
| Profit before tax | 325.70 | 194.90 | +67.1% | 132.20 | +146.4% |
| Net profit for the period | 238.40 | 145.90 | +63.4% | 90.40 | +163.7% |
| EPS, basic (₹) | 103.51 | 63.35 | +63.4% | 39.25 | +163.7% |
| Net margin (%) | 33.7 | 20.1 | 13.1 |
Standalone
- Filed with BSE
- 27 Apr 2022, 16:09 IST
- Board meeting
- 26 Apr 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE